Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (65 records) with 2024 (77) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,266 records in scope (CR5), not by the ranked leaders only.
This dataset tracks patent families combining bio-based polymer, polylactic acid and polyhydroxyalkanoate terminology in the title/abstract with degradation, blend-modification and heat-performance language in the claims, filtered to condensation-polymer, polymer-composition and fermentation IPC codes. It spans filings from 2015 through the 2026 data cut-off, covering 1,266 published records across six major receiving offices.
The corpus concentrates on polymer composition and blend-modification work rather than upstream fermentation chemistry, which shows up as a smaller but still substantial C12P count. That split matters for anyone deciding whether to file on formulation or on the biosynthetic route itself.
Two views of the same corpus: the year-by-year filing count, and how records distribute across the eight IPC subclasses that define this space.
Filings rose from 54 in 2017 to a peak of 77 in 2024, passing through 49 at the 2022 midpoint. That trajectory reads as flat-to-declining rather than compounding growth, and the 2025-2026 figures are still understated by the roughly 18-month gap between filing and publication.
C08L (polymer compositions) accounts for 1,048 of 1,266 records, well ahead of C08G condensation polymers (415), C08J processing/solutions (398) and C08K additives (365). Laminate work under B32B (195) and shaping under B29C (160) trail behind, and C12P fermentation synthesis (119) is the smallest major bucket — evidence that most recent claim activity is downstream of the base polymer, not on how it is made.
Shares are the percentage of the 1,266 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about bio-based and biodegradable polymers and every answer comes back with the patent numbers behind it.
Try EurekaKingfa's filing claims a polylactic acid composite defined by three components in fixed weight ranges — 89 to 98 parts PLA, 1 to 4 parts talcum powder within a specified particle-size window, and 1 to 7 parts plasticizer within a specified molecular-weight range — plus a polydispersity index constraint on the PLA itself (1.55 to 2.02).Filed 2020-09-17.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5883199A | Polylactic acid-based blends | 443 |
| 2 | US20040231845A1 | Applications of degradable polymers in wells | 319 |
| 3 | WO1990001521A1 | Degradable thermoplastic from lactides | 282 |
| 4 | US5939467A | Biodegradable polymeric compositions and products thereof | 247 |
| 5 | US6135987A | Synthetic fiber | 242 |
| 6 | US6905987B2 | Fibers comprising polyhydroxyalkanoate copolymer/polylactic acid polymer or copolymer blends | 163 |
| 7 | US6043063A | Methods of PHA extraction and recovery using non-halogenated solvents | 145 |
| 8 | WO1995020615A1 | Biodegradable copolymers and plastic articles comprising biodegradable copolymers of 3-hydroxyhexanoate | 144 |
| 9 | US5990271A | Films and absorbent articles comprising a biodegradable polyhydroxyalkanoate comprising 3-hydroxybutyrate and… | 141 |
| 10 | US6869985B2 | Environmentally friendly polylactide-based composite formulations | 127 |
Citation counts favour older filings simply because they have had longer to accumulate references — treat this as a map of foundational prior art, not of current-day importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three readings of the dataset that matter more than any single ranking.
The peak of 77 filings in 2024 followed a midpoint of 49 in 2022 and an opening figure of 54 in 2017 — a curve that moves sideways more than it climbs. For a field this often gets pitched as emerging, the filing data reads as settled.
Polymer-composition claims (C08L) appear in the large majority of records, more than double the next subclass. Fermentation and enzymatic synthesis (C12P) is the smallest major category at 119 — the upstream biosynthetic route is comparatively open.
The United States, EPO and WIPO/PCT each receive well over 150 filings, with Canada, Australia and China each in the 77-91 range. No single office dominates the way it might in a narrower or newer technology.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bio-based and biodegradable polymers, with the prior art for and against each one.
Leading assignees in this space include established consumer-goods and specialty-chemicals filers, but the momentum data complicates any simple leader narrative.
Assignees including major consumer-products and chemicals companies all register zero filings in the latest tracked year, with one showing a -100% year-over-year change. Given the roughly 18-month publication lag, some of this is an artefact of timing rather than genuine withdrawal — but it is consistent enough across leaders to warrant checking each filer's own recent activity directly.
Only ten co-assignee pairs appear in the corpus, with the strongest pairs linked by shared filings of 8 and 6. This is a field where most patents are filed by a single assignee rather than through joint-venture or cross-licensing structures.
Filing is distributed across the United States, Europe, the PCT route, Canada, Australia and China, each above 75 filings. A freedom-to-operate check limited to one or two offices will miss a meaningful share of the active claim set.
| Assignee | Recent year | YoY |
|---|---|---|
| Procter & Gamble | 0 | — |
| Metabolix, Inc. | 0 | — |
| BASF SE | 0 | -100% |
| Avantium | 0 | — |
| Novamont S.p.A. | 0 | — |
| Monsanto Company (US) | 0 | — |
| Kimberly-Clark Worldwide, Inc. | 0 | — |
| AgriPlast Ltd. | 0 | — |
Three directions for a team deciding where to file or where to watch.
C12P fermentation and enzymatic synthesis records are the smallest major IPC bucket in this corpus. If the composition side is crowded, the biosynthetic upstream may still have room.
Explore synthesis-route filingsZero-filing signals from established assignees may reflect publication lag rather than exit. Cross-check against each company's most recent disclosed applications before assuming withdrawal.
Track assignee activityCanada, Australia and China each carry a meaningful filing share. A jurisdiction review limited to the US and Europe will understate the active footprint.
Compare jurisdiction coverageThe most-cited records in this corpus are foundational PLA blend and degradable-thermoplastic patents dating back to the 1990s, including filings on polylactic acid-based blends and degradable thermoplastics from lactides. These older filings accumulate citations simply by having been available longer, so high citation counts should be read as a map of influential prior art rather than a ranking of current market leaders. Newer formulation patents, such as the Kingfa PLA composite filing, claim narrower and more specific parameter windows within that established territory.
Not clearly. Filings rose from 54 in 2017 to a peak of 77 in 2024, but passed through only 49 at the 2022 midpoint, which is a flat-to-declining trajectory rather than sustained growth. The 2025 and 2026 figures are additionally understated because publication typically lags filing by around 18 months, so the most recent one to two years will always look thinner than they eventually turn out to be. Treat the current curve as a mature filing pattern rather than an emerging one.
C08L, covering polymer compositions, accounts for 1,048 of the 1,266 tracked records and is by far the densest subclass. C08G condensation polymers, C08J polymer processing, and C08K additives each sit in the 365-415 range, while C12P fermentation and enzymatic synthesis is the smallest major category at 119. This distribution shows that most recent claim activity targets how the polymer is formulated and processed, not how the base material is biosynthesized.
Several established filers in this dataset, including major consumer-goods and specialty-chemicals companies, register no filings in the latest tracked year, and at least one shows a -100% year-over-year change. Part of this is a publication-lag artefact: patent applications typically surface in public databases about 18 months after filing, so the most recent year is structurally incomplete for every assignee. Before concluding a company has exited the space, check its filings from the prior one to two years and any continuation applications still working through the pipeline.
Fermentation and enzymatic synthesis (C12P) is the smallest major IPC bucket in this corpus at 119 records, well behind the 1,048 in polymer compositions, suggesting upstream biosynthetic routes carry less claim density than downstream formulation work. Specific under-claimed pockets include enzymatic PHA biosynthesis pathways, heat-deflection-temperature-focused blend additives, and compostability-grade laminate structures under B32B. Co-assignment is also rare across the dataset, with only ten co-assignee pairs identified, meaning collaborative filing structures remain uncommon and open.
Go past this page: query the whole bio-based and biodegradable polymers corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.